Harness Therapeutics is seeking a Research Project Manager to drive the planning, coordination, and execution of our research programs at the Babraham Research Campus in Cambridge, one of the UK’s leading biotech hubs. The role presents an excellent opportunity for a talented and dynamic individual to advance their career and join an evolving biotech that is focused on the development of RNA-targeted therapeutics in neurodegenerative disease.
Celebrating the Canada-UK Biomanufacturing Partnership and a delegation of Canadian life sciences companies visiting London, the event will bring together leaders from industry, investment and innovation for a panel discussion exploring what influences where high-growth life sciences companies choose to scale.
The conversation will cover key considerations including access to capital, talent, infrastructure and markets, as well as the opportunities for collaboration between the Canadian and UK life sciences ecosystems.
Do you want to help us improve human health and understand life on Earth? Make your mark by shaping the future to enable or deliver life-changing science to solve some of humanity’s greatest challenges.
Join us at our annual Life Sciences Conference, “Rewiring the legal protection of drug discovery: AI, data and innovation”, where our life sciences sector team, alongside industry experts, will explore how artificial intelligence is reshaping the discovery and development of new medicines.
Join the Eastern England Secure Data Environment (SDE) and Health Innovation East Midlands for the launch of a new webinar series demonstrating how the Eastern England SDE can support research and innovation by providing secure access to de-identified NHS patient data for analysis.
*Guest article by LimestoneGrey. If you would like to submit an article or blog post please email [email protected].
by Philippa Clark, Director of Business Development, One Nucleus
Help build the future of drug safety monitoring
Drug-induced toxicity remains one of the biggest causes of drug-development delay, clinical failure and patient harm. Current monitoring is often insensitive, organ-specific and reliant on damage becoming clinically apparent. We think there is a better way.